Embryonic vascular disruption adverse outcomes: Linking high-throughput signaling signatures with functional consequences

Reproductive Toxicology

Volumn 71, Issue , 2017, Pages 16-31

  Ellis Hutchings, Robert G ^a   Settivari, Raja S ^a   McCoy, Alene T ^a   Kleinstreuer, Nicole ^b   Franzosa, Jill ^c   Knudsen, Thomas B ^c   Carney, Edward W ^a  

^a DOW CHEMICAL COMPANY   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

5HPP 33; Embryo; Functional in vitro assay; TNP 470; ToxCast; Vascular disruption

Indexed keywords

5HPP 33; FUMAGILLOL CHLOROACETYLCARBAMATE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ADVERSE OUTCOME; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL TOXICITY; EMBRYO; EMBRYO DEVELOPMENT; EMBRYOTOXICITY; FEMALE; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; RAT; VASCULAR DISEASE; VASCULAR DISRUPTION; ZEBRA FISH;

EID: 85018524242     PISSN: 08906238     EISSN: 18731708     Source Type: Journal    
DOI: 10.1016/j.reprotox.2017.04.003     Document Type: Article

References (78)

1. [1] Chung, A.S., Ferrara, N., Developmental and pathological angiogenesis. Annu. Rev. Cell Dev. Biol. 27 (2011), 563–584.
2. [2] Husain, T., et al. Descriptive epidemiologic features shared by birth defects thought to be related to vascular disruption in Texas: 1996–2002. Birth Defects Res. A Clin. Mol. Teratol. 82:6 (2008), 435–440.
3. [3] Shalaby, F., et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376:6535 (1995), 62–66.
4. [4] Cerdeira, A.S., Karumanchi, S.A., Angiogenic factors in preeclampsia and related disorders. Cold. Spring Harb. Perspect. Med., 2(11), 2012.
5. [5] Rutland, C.S., et al. Maternal administration of anti-angiogenic agents, TNP-470 and Angiostatin4. 5, induces fetal microphthalmia. Mol. Vis. 15 (2009), 1260–1269.
6. [6] D'Amato, R.J., et al. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 91:9 (1994), 4082–4085.
7. [7] van Gelder, M.M., et al. Teratogenic mechanisms of medical drugs. Hum. Reprod. Update 16:4 (2010), 378–394.
8. [8] Gold, N.B., Westgate, M.N., Holmes, L.B., Anatomic and etiological classification of congenital limb deficiencies. Am. J. Med. Genet. A 155A:6 (2011), 1225–1235.
9. [9] Therapontos, C., et al. Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation. Proc. Natl. Acad. Sci. U. S. A. 106:21 (2009), 8573–8578.
10. [10] Kleinstreuer, N.C., et al. Environmental impact on vascular development predicted by high-throughput screening. Environ. Health Perspect. 119:11 (2011), 1596–1603.
11. [11] Knudsen, T.B., Kleinstreuer, N.C., Disruption of embryonic vascular development in predictive toxicology. Birth Defects Res. C Embryo Today 93:4 (2011), 312–323.
12. [12] Kavlock, R., et al. Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. Chem. Res. Toxicol. 25:7 (2012), 1287–1302.
13. [13] Birnbaum, L.S., My winding road: from microbiology to toxicology and environmental health. Annu. Rev. Pharmacol. Toxicol. 56 (2016), 1–17.
14. [14] Sipes, N.S., et al. Predictive models of prenatal developmental toxicity from ToxCast high-throughput screening data. Toxicol. Sci. 124:1 (2011), 109–127.
15. [15] Kleinstreuer, N.C., et al. A computational model predicting disruption of blood vessel development. PLoS Comput. Biol., 9(4), 2013, e1002996.
16. [16] Berridge, B.R., et al. Technological advances in cardiovascular safety assessment decrease preclinical animal use and improve clinical relevance. ILAR J. 57:2 (2016), 120–132.
17. [17] Atienzar, F.A., et al. Predictivity of dog co-culture model: primary human hepatocytes and HepG2 cells for the detection of hepatotoxic drugs in humans. Toxicol. Appl. Pharmacol. 275:1 (2014), 44–61.
18. [18] Staton, C.A., Reed, M.W., Brown, N.J., A critical analysis of current in vitro and in vivo angiogenesis assays. Int. J. Exp. Pathol. 90:3 (2009), 195–221.
19. [19] Ellis-Hutchings, R.G., Carney, E.W., Whole embryo culture: a New technique that enabled decades of mechanistic discoveries. Birth Defects Res. B Dev. Reprod. Toxicol. 89:4 (2010), 304–312.
20. [20] Panzica-Kelly, J.M., et al. Morphological score assignment guidelines for the dechorionated zebrafish teratogenicity assay. Birth Defects Res. B Dev. Reprod. Toxicol. 89:5 (2010), 382–395.
21. [21] Wilson, V., Beddington, R.S., Cell fate and morphogenetic movement in the late mouse primitive streak. Mech. Dev. 55:1 (1996), 79–89.
22. [22] Fleming, A., et al. Mechanisms of normal and abnormal neurulation: evidence from embryo culture studies. Int. J. Dev. Biol. 41:2 (1997), 199–212.
23. [23] Foerst-Potts, L., Sadler, T.W., Disruption of Msx-1 and Msx-2 reveals roles for these genes in craniofacial, eye, and axial development. Dev. Dyn. 209:1 (1997), 70–84.
24. [24] Osumi-Yamashita, N., Ninomiya, Y., Eto, K., Mammalian craniofacial embryology in vitro. Int. J. Dev. Biol. 41:2 (1997), 187–194.
25. [25] Nakagawa, M., et al. Analysis of heart development in cultured rat embryos. J. Mol. Cell. Cardiol. 29:1 (1997), 369–379.
26. [26] Ellis-Hutchings, R.G., et al. In vitro screening methods for developmental toxicology. Hood, R., (eds.) Developmental and Reproductive Toxicology, a Practical Approach, 3rd edition, 2011, Taylor and Francis.
27. [27] Chimote, G., et al. Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery. Drug Des Devel Ther 8 (2014), 1107–1123.
28. [28] Stainier, D.Y., Fishman, M.C., The zebrafish as a model system to study cardiovascular development. Trends Cardiovasc. Med. 4:5 (1994), 207–212.
29. [29] Bohnsack, B.L., et al. Signaling hierarchy downstream of retinoic acid that independently regulates vascular remodeling and endothelial cell proliferation. Genes Dev. 18:11 (2004), 1345–1358.
30. [30] Jojovic, M., Wolf, F., Mangold, U., Epidermal growth factor: vascular endothelial growth factor and progesterone promote placental development in rat whole-embryo culture. Anat. Embryol. (Berl.) 198:2 (1998), 133–139.
31. [31] Nagase, T., et al. Hedgehog signalling in vascular development. Angiogenesis 11:1 (2008), 71–77.
32. [32] Noguchi, T., et al. Angiogenesis inhibitors derived from thalidomide. Bioorg. Med. Chem. Lett. 15:24 (2005), 5509–5513.
33. [33] Ema, M., et al. Fetal malformations and early embryonic gene expression response in cynomolgus monkeys maternally exposed to thalidomide. Reprod. Toxicol. 29:1 (2010), 49–56.
34. [34] Kizaki, M., Hashimoto, Y., New tubulin polymerization inhibitor derived from thalidomide: implications for anti-myeloma therapy. Curr. Med. Chem. 15:8 (2008), 754–765.
35. [35] Li, P.K., et al. A thalidomide analogue with in vitro antiproliferative: antimitotic, and microtubule-stabilizing activities. Mol. Cancer Ther. 5:2 (2006), 450–456.
36. [36] Rashid, A., et al. Thalidomide (5HPP-33) suppresses microtubule dynamics and depolymerizes the microtubule network by binding at the vinblastine binding site on tubulin. Biochemistry 54:12 (2015), 2149–2159.
37. [37] Iguchi, T., et al. Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: possible anti-myeloma mechanism of thalidomide. Int. J. Mol. Med. 21:2 (2008), 163–168.
38. [38] Shimura, M., et al. Novel compound SK-1009 suppresses interleukin-6 expression through modulation of activation of nuclear factor-kappaB pathway. Biol. Pharm. Bull. 35:12 (2012), 2186–2191.
39. [39] Logothetis, C.J., et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin. Cancer Res. 7:5 (2001), 1198–1203.
40. [40] Cline, E.I., et al. Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling. Cancer Res. 62:24 (2002), 7143–7148.
41. [41] Klauber, N., et al. Critical components of the female reproductive pathway are suppressed by the angiogenesis inhibitor AGM-1470. Nat. Med. 3:4 (1997), 443–446.
42. [42] Vetro, J.A., Dummitt, B., Chang, Y.-H., Methionine aminopeptidase. Lendeckel, H.A., (eds.) Aminopeptidases in Biology and Disease, 2004, Kluwer Academic/Plenum Publishers, New York, 17–44.
43. [43] Yeh, J.R., et al. Targeted gene disruption of methionine aminopeptidase 2 results in an embryonic gastrulation defect and endothelial cell growth arrest. Proc. Natl. Acad. Sci. U. S. A. 103:27 (2006), 10379–10384.
44. [44] McCollum, C.W., et al. Identification of vascular disruptor compounds by analysis in zebrafish embryos and mouse embryonic endothelial cells. Reprod. Toxicol., 2016 pii/S0890623816304014.
45. [45] Knudsen, T.B., Sarkanen, R., Spencer, R.S., Baker, N.C., Franzosa, J.A., Tal, T., Kleinstreuer, N.C., Cai, B.B., Berg, E.L., Heinonen, T., ToxCast Model-Based Prediction of Human Vascular Disruption: correlation to endothelial tubulogenesis assays and computer simulation. Reprod. Toxicol., 2017 in preparation.
46. [46] Franzosa, J.A., Ellis-Hutchings, R.G., Kleinstreuer, N.C., Houck, K.A., Carney, E.W., Knudsen, T.B., RNA-Seq analysis of the functional-link between vascular disruption and adverse developmental consequences. Reprod. Toxicol., 2017 in preparation.
47. [47] Attene-Ramo, M.S., et al. The Tox21 robotic platform for the assessment of environmental chemicals?from vision to reality. Drug Discov. Today 18:15–16 (2013), 716–723.
48. [48] Judson, R., et al. Analysis of the effects of cell stress and cytotoxicity on In vitro assay activity across a diverse chemical and assay space. Toxicol. Sci., 153(2), 2016, 409.
49. [49] Tal, T., Kilty, C., Smith, A., LaLone, C., Kennedy, B., Tennant, A., McCollum, C.W., Bondesson, M., Knudsen, T., Padilla, S., Kleinstreuer, N., 2016. Screening for angiogenic inhibitors in zebrafish to evaluate a predictive model for developmental vascular toxicity. Reprod. Toxicol., 2016 Epub date: 12/23/2016.
50. [50] Cockroft, D., Copp, A., Cockroft, D., (eds.) Dissection and Culture of Postimplantation Embryos, in Postimplantation Culture of Mammalian Embryos-a Practical Approach, 1990, Oxford University Press, Oxford, 15–40.
51. [51] Daston, G.P., et al. Difference in teratogenic potency of ethylenethiourea in rats and mice: relative contribution of embryonic and maternal factors. Teratology 40:6 (1989), 555–566.
52. [52] Brown, N.A., Fabro, S., Quantitation of rat embryonic development in vitro: a morphological scoring system. Teratology 24:1 (1981), 65–78.
53. [53] Lowry, O.H., et al. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1 (1951), 265–275.
54. [54] Westerfield, M., The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Danio Rerio). 5th ed., 2007, University of Oregon Press, Eugene, OR.
55. [55] Abassi, Y.A., et al. Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. Chem. Biol. 16:7 (2009), 712–723.
56. [56] Kimmel, C.B., et al. Stages of embryonic development of the zebrafish. Dev. Dyn. 203:3 (1995), 253–310.
57. [57] OECD, Test No. 236: Fish Embryo Acute Toxicity (FET) Test. 2013, OECD Publishing.
58. [58] Gustafson, A.L., et al. Inter-laboratory assessment of a harmonized zebrafish developmental toxicology assay – progress report on phase I. Reprod. Toxicol. 33:2 (2012), 155–164.
59. [59] Selderslaghs, I.W., Blust, R., Witters, H.E., Feasibility study of the zebrafish assay as an alternative method to screen for developmental toxicity and embryotoxicity using a training set of 27 compounds. Reprod. Toxicol. 33:2 (2012), 142–154.
60. [60] Motulsky, H.J., Christopoulos, A., Fitting Models to Biological Data Using Linear and Nonlinear Regression: a Practical Guide to Curve Fitting, in GraphPad Software, Inc. 2003, Oxford University Press, San Diego, CA.
61. [61] Franzosa, J., et al. RNA-Seq analysis of the functional link between vascular disruption and adverse developmental consequences. The Toxicologist, Supplement to Toxicological Sciences, 2014 p. 456.
62. [62] Kleinstreuer, N.C., et al. Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms. Nat. Biotechnol. 32:6 (2014), 583–591.
63. [63] Houck, K.A., et al. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J. Biomol. Screen. 14:9 (2009), 1054–1066.
64. [64] Vichai, V., Kirtikara, K., Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat. Protoc. 1:3 (2006), 1112–1116.
65. [65] Lee, C.J., et al. Fluorothalidomide: a characterization of maternal and developmental toxicity in rabbits and mice. Toxicol. Sci. 122:1 (2011), 157–169.
66. [66] Beedie, S.L.et al., In vivo screening and discovery of novel candidate thalidomide analogs in the zebrafish embryo and chicken embryo model systems. Oncotarget, 2016.
67. [67] Padilla, S., et al. Zebrafish developmental screening of the ToxCast Phase I chemical library. Reprod. Toxicol. 33:2 (2012), 174–187.
68. [68] Truong, L., et al. Multidimensional in vivo hazard assessment using zebrafish. Toxicol. Sci. 137:1 (2014), 212–233.
69. [69] Didcock, K., Jackson, D., Robson, J.M., The action of some nucleotoxic substances on pregnancy. Br. J. Pharmacol. Chemother. 11:4 (1956), 437–441.
70. [70] Prakash, V., Timasheff, S.N., Aging of tubulin at neutral pH: stabilization by colchicine and its analogues. Arch. Biochem. Biophys. 295:1 (1992), 146–452.
71. [71] Luo, J., et al. Placental abnormalities in mouse embryos lacking the orphan nuclear receptor ERR-beta. Nature 388:6644 (1997), 778–782.
72. [72] Latos, P.A., et al. Fgf and Esrrb integrate epigenetic and transcriptional networks that regulate self-renewal of trophoblast stem cells. Nat. Commun., 6, 2015, 7776.
73. [73] Marlow, F., et al. No tail co-operates with non-canonical Wnt signaling to regulate posterior body morphogenesis in zebrafish. Development 131:1 (2004), 203–216.
74. [74] Yamaguchi, T.P., et al. A Wnt5a pathway underlies outgrowth of multiple structures in the vertebrate embryo. Development 126:6 (1999), 1211–1223.
75. [75] Ma, A.C., et al. Methionine aminopeptidase 2 is required for HSC initiation and proliferation. Blood 118:20 (2011), 5448–5457.
76. [76] Morello, F., et al. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms. Atherosclerosis 207:1 (2009), 38–44.
77. [77] Kim, K.H., Young, B.D., Bender, J.R., Endothelial estrogen receptor isoforms and cardiovascular disease. Mol. Cell. Endocrinol. 389:1-2 (2014), 65–70.
78. [78] Stefater 3rd, J.A., et al. Regulation of angiogenesis by a non-canonical Wnt-Flt1 pathway in myeloid cells. Nature 474:7352 (2011), 511–515.